menu
    • menu
    [{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Adagene Suzhou Limited"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Factor Bioscience","sponsor":"Tempest Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Amezalpat","moa":"PPAR alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Factor Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Factor Bioscience \/ Tempest Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Factor Bioscience \/ Tempest Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Amezalpat

    Menu

    Amezalpat

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Factor Bioscience

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Factor Bioscience

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Tempest Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Tempest Acquires Dual-CAR T Programs, Extends Runway to Mid 2027 from Factor

                            Details : Under the acquisition of Amezalpat, the deal aims to advance treatment for Extramedullary disease (EMD) targeting PPAR alpha.

                            Product Name : TPST-1120

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 19, 2025

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Tempest Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest gets FDA Fast Track for Amezalpat in Hepatocellular Carcinoma

                            Details : TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2025

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest’s Amezalpat Receives FDA Orphan Drug Designation for HCC

                            Details : TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest Receives FDA Approval for Amezalpat Hepatocellular Carcinoma Trial

                            Details : TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 12, 2024

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tempest and Roche Partner to Advance Amezalpat in Hepatocellular Carcinoma Trial

                            Details : The agreement aims to advance the evaluation of TPST-1120 (amezalpat) as combination with Tecentriq (atezolizumab) and bevacizumab, for the first-line treatment of hepatocellular carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest Announces Successful FDA Meeting for Amezalpat in Liver Cancer Treatment

                            Details : TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 15, 2024

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest's Amezalpat Shows 6-month Survival Gain in HCC Study

                            Details : TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 20, 2024

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Random...

                            Details : TPST-1120 is an oral, small molecule, selective PPAR alpha antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for unresectable or metastatic hepatocellular carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 11, 2023

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Adagene Suzhou Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in F...

                            Details : TPST-1120 is an oral, small molecule, selective PPAR⍺ antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for hepatocellular carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 28, 2023

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Adagene Suzhou Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line...

                            Details : TPST-1120 target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a monotherapy or in combination with other approved agents.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 27, 2023

                            Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.